This is a multicenter, intra-subject dose-titration open-label study of nevanimibe
hydrochloride (HCl) for the treatment of classic congenital adrenal hyperplasia (CAH).
Following a Screening Period of approximately 2-14 weeks, eligible subjects will enter a
Baseline Period of approximately 2-8 weeks and then a 16-week Treatment Period. It is
anticipated that the overall duration of the study per subject will range from 24-42 weeks.